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In this issue of Critical Care, Christensen and colleagues 
[1] present data suggesting that patients who chronically 
take statins have improved survival during acute 
hospitalizations and for at least 1 year thereafter. Statins 
are now recognized to have numerous pleiotropic (Greek 
pleion [many] + tropos [turns]) eﬀ   ects. As a pharma-
ceutical drug class, statins inhibit the reduction of 
hydroxymethyl-glutaryl-CoA (HMG-CoA reductase) to 
mevalonate. Mevalonate is a substrate for cholesterol 
synthesis, hence the use of statins for control of hyper-
cholesterolemia. Mevalonate is also involved in the 
synthesis of bile acids, certain steroid hormones, and 
vitamin D. Statins also inhibit the production of cyclo-
oxygenase-2 (COX-2) protein and are upstream in the 
biosynthesis of ubiquinone (mitochondrial respiration) 
and heme-A (oxygen transport) and prenalation of small 
G proteins acting as molecular switches. All of these 
compounds or processes have at one time or another 
been implicated in the altered physiology of sepsis, 
trauma, and other systemic injuries. It is the role of 
mevalonate in the prenalation of G proteins that is 
perhaps the most far-reaching with regard to acute illness 
because of the profound eﬀ  ect this process can have on 
inﬂ  ammatory cell activation and inﬂ  ammatory protein 
production [2].
Beneﬁ  cial  eﬀ   ects of statins have been suggested for 
many diseases not directly related to cholesterol metabo-
lism, including diabetes, multiple sclerosis, Alzheimer 
disease, arthritis, bone repair, anti-phospho  lipid syn-
drome, and multiple myeloma. In well-controlled animal 
models of pneumococcal pneumonia, statins have been 
shown to improve survival [3]. A recent meta-analysis of 
observational studies of the impact of statins in 
hospitalized patients by Tleyjeh and colleagues [4] 
showed that statins not only were associated with 
profoundly improved outcomes of patients admitted with 
infections (odds ratio 0.55, conﬁ  dence interval [CI] 0.36 
to 0.83) but also seemed to be associated with a reduction 
in the development of infection in high-risk patients 
(odds ratio 0.57, CI 0.43 to 0.75).
Th  e work by Christensen and colleagues [1] brings 
forward perhaps the largest and most complete obser-
vational dataset to date, and they are to be commended 
for providing the ﬁ  rst data on long-term follow-up in 
studies of this type. Th   ese data conﬁ  rm the previous work 
on statins demonstrating an association between the 
prior use of this class of drugs and reduced hospital 
mortality. In the present study, the population of patients 
is large enough to allow for robust adjustments for co-
morbidities, extensive subset analysis, and development 
of propensity scores. One of the most striking subgroups 
in which beneﬁ  ts were observed related to the particular 
statin (simvastatin), which is lipophilic and is the most 
commonly used clinically, versus the others, which were 
hydrophilic. Th   e hydrophilic group was quite small, how-
ever. Th   ere is a large body of in vitro work examining the 
pleiotropic actions of statins according to the degree of 
lipophilicity versus hydrophilicity. In this regard, 
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From the earliest studies of statins for control of 
plasma cholesterol, observations have been made 
that the reductions in mortality observed occurred in 
a manner seemingly independent from what could 
be anticipated from cholesterol lowering alone. Over 
the last decade, the pleiotropic eff  ects of statins 
have been increasingly elucidated. Perhaps most 
intriguing are the eff  ects statins appear to have on the 
immune system, especially the modulation of diff  use 
or systemic infl  ammation. There is a growing body of 
observational literature suggesting that statins can 
actually reduce hospital mortality through mechanisms 
far beyond those that can be explained by reductions 
in cardiovascular events.
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clear that this will translate into better in vivo results [5].
Adding strength to the association observed by 
Christensen and colleagues [1], current users, new users, 
and long-term users derived similar beneﬁ  t  whereas 
users of other cholesterol-lowering drugs had no asso-
ciated beneﬁ  t and indeed eﬀ  ects seemed to go the wrong 
direction. Other subgroups that faired the best with 
statin use include patients with gastrointestinal disease, 
trauma, poisoning, cancer, or mechanical ventilation. 
Eﬀ  ects did not seem to diﬀ  er as to whether the patient 
was surgical or medical. Th  e survival beneﬁ  t persisted 
out to 1 year of follow-up. At least one randomized trial 
in critically ill patients with infection has been completed. 
It was not large enough to address clinical outcomes but 
did demonstrate a reduction in inﬂ  ammatory cytokines 
in the statin arm [6].
Given the results derived from observational data from 
a very large and still rapidly growing literature on the 
beneﬁ  ts of statins, prospective randomized trials are now 
clearly indicated. At least one such trial, conducted by 
the National Institutes of Health ARDS [Acute 
Respiratory Distress Syndrome] Clinical Trials Network 
[7], is targeting an enrollment of 1,000 patients and is 
under way in patients with acute lung injury (ALI) due to 
infection. Several aspects of statins, including the 
simplicity with which statins can be used in the hospital 
setting, their low cost, and their relative safety, make the 
opportunity to evaluate this class of agents in prospective 
trials even more exciting. Th   ese drugs have the potential 
to actually prevent the development of sepsis, make 
sepsis less severe, reduce the incidence of ALI/ARDS, 
and reduce mortality.
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